Gland Pharma announced second quarter results: profit fell 15.74% year-on-year

Gland Pharma second quarter results live broadcast: Gland Pharma announced its second quarter results on November 4, 2024. Revenue increased by 2.36% year-on-year, while profit fell sharply by 15.74%. Compared with the previous quarter, revenue increased by 0.29% and profit increased by 13.75%.

The company’s selling, general and administrative expenses increased by 3.29% year-on-year, but fell by 6.68% month-on-month. This volatility highlights the challenges Gland Pharma faces in managing costs in changing market conditions.

Operating income increased significantly by 17.86% month-on-month, but fell 16.29% year-on-year. This difference suggests that while the company is improving short-term operating efficiency, it is struggling to maintain long-term profitability.

Second quarter earnings per share (EPS) was $9.93, a year-on-year decrease of 15.7%. The decline in earnings per share reflects an overall decline in Gland Pharma’s current profitability.

In terms of stock performance, Gland Pharma returned -0.84% ​​last week, -5.42% over the past six months, and -16.3% year-to-date. The numbers suggest the company faces challenging market conditions, affecting investor sentiment.

As of now, Gland Pharma has a market capitalization of $26,539.86 Crores, a new 52-week high $2,220.95 The lowest price is $1,509.30. These indicators suggest that the company’s stock has been volatile over trading cycles.

Analysts are divided, with 2 in 10 rating the stock a Strong Sell rating, 4 recommending a Sell, 1 advising a Hold, and 3 advocating a Strong Buy. As of November 5, 2024, the consensus recommendation is Hold, indicating cautious optimism among some market experts.